{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:13:39Z","timestamp":1785543219853,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10928-019-09642-7","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T17:57:12Z","timestamp":1558720632000},"page":"441-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy"],"prefix":"10.1007","volume":"46","author":[{"name":"the Duchenne Muscular Dystrophy Regulatory Science Consortium (D-RSC)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela J.","family":"Conrado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Larkindale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micki","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Abresch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Bronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglass","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Gordish-Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Harnisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Henricson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Vong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"key":"9642_CR1","unstructured":"PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2018 through 2022. \n                    https:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM511438.pdf"},{"issue":"109S","key":"9642_CR2","first-page":"S65","volume":"15","author":"DJ Conrado","year":"2017","unstructured":"Conrado DJ, Karlsson MO, Romero K, Sarr C, Wilkins JJ (2017) Open innovation: towards sharing of data, models and workflows. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 15(109S):S65\u2013S71","journal-title":"Eur J Pharm Sci Off J Eur Fed Pharm Sci."},{"issue":"9","key":"9642_CR3","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jalz.2016.05.005","volume":"12","author":"M Haas","year":"2016","unstructured":"Haas M, Stephenson D, Romero K, Gordon MF, Zach N, Geerts H, Brain Health Modeling Initiative (BHMI) (2016) Big data to smart data in Alzheimer\u2019s disease: real-world examples of advanced modeling and simulation. Alzheimers Dement J Alzheimers Assoc. 12(9):1022\u20131030","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"issue":"1","key":"9642_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3233\/JAD-130575","volume":"37","author":"K Ito","year":"2013","unstructured":"Ito K, Corrigan B, Romero K, Anziano R, Neville J, Stephenson D, Lalonde R (2013) Understanding placebo responses in Alzheimer\u2019s disease clinical trials from the literature meta-data and CAMD database. J Alzheimers Dis JAD. 37(1):173\u2013183","journal-title":"J Alzheimers Dis JAD."},{"issue":"3","key":"9642_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.16","volume":"97","author":"K Romero","year":"2015","unstructured":"Romero K, Ito K, Rogers JA, Polhamus D, Qiu R, Stephenson D, Mohs R, Lalonde R, Sinha V, Wang Y, Brown D, Isaac M, Vamvakas S, Hemmings R, Pani L, Bain LJ, Corrigan B, Alzheimer\u2019s Disease Neuroimaging Initiative, Coalition Against Major Diseases (2015) The future is now: model-based clinical trial design for Alzheimer\u2019s disease. Clin Pharmacol Ther 97(3):210\u2013214","journal-title":"Clin Pharmacol Ther"},{"issue":"9 Suppl","key":"9642_CR6","doi-asserted-by":"publisher","first-page":"9S","DOI":"10.1177\/0091270010377788","volume":"50","author":"K Romero","year":"2010","unstructured":"Romero K, Corrigan B, Tornoe CW, Gobburu JV, Danhof M, Gillespie WR, Gastonguay MR, Meibohm B, Derendorf H (2010) Pharmacometrics as a discipline is entering the \u201cindustrialization\u201d phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol 50(9 Suppl):9S\u201319S","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"9642_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10928-014-9390-0","volume":"41","author":"K Romero","year":"2014","unstructured":"Romero K, Sinha V, Allerheiligen S, Danhof M, Pinheiro J, Kruhlak N, Wang Y, Wang S-J, Sauer J-M, Marier JF, Corrigan B, Rogers J, Lambers Heerspink HJ, Gumbo T, Vis P, Watkins P, Morrison T, Gillespie W, Gordon MF, Stephenson D, Hanna D, Pfister M, Lalonde R, Colatsky T (2014) Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. J Pharmacokinet Pharmacodyn 41(6):545\u2013552","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9642_CR8","unstructured":"FAQs About Rare Diseases|Genetic and Rare Diseases Information Center (GARD)\u2014an NCATS Program [Internet]. [cited 2019 Jan 9]. \n                    https:\/\/rarediseases.info.nih.gov\/diseases\/pages\/31\/faqs-about-rare-diseases"},{"issue":"1","key":"9642_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev.pharmtox.011008.145613","volume":"49","author":"JVS Gobburu","year":"2009","unstructured":"Gobburu JVS, Lesko LJ (2009) Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol 49(1):291\u2013301","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"9642_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1542\/peds.2014-2044","volume":"135","author":"PA Romitti","year":"2015","unstructured":"Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GKD, Ciafaloni E, Cunniff C, Druschel CM, Mathews KD, Matthews DJ, Meaney FJ, Andrews JG, Conway KMC, Fox DJ, Street N, Adams MM, Bolen J, on behalf of the MD STARnet (2015) Prevalence of Duchenne and Becker Muscular Dystrophies in the United States. Pediatrics 135(3):513\u2013521","journal-title":"Pediatrics"},{"issue":"3","key":"9642_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","volume":"53","author":"A Aartsma-Rus","year":"2016","unstructured":"Aartsma-Rus A, Ginjaar IB, Bushby K (2016) The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet 53(3):145\u2013151","journal-title":"J Med Genet"},{"issue":"10119","key":"9642_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, Clemens PR, Hoffman EP, Cnaan A, Gordish-Dressman H (2018) Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. The Lancet. 391(10119):451\u2013461","journal-title":"The Lancet."},{"issue":"5","key":"9642_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/mus.26161","volume":"58","author":"H Arora","year":"2018","unstructured":"Arora H, Willcocks RJ, Lott DJ, Harrington AT, Senesac CR, Zilke KL, Daniels MJ, Xu D, Tennekoon GI, Finanger EL, Russman BS, Finkel RS, Triplett WT, Byrne BJ, Walter GA, Sweeney HL, Vandenborne K (2018) Longitudinal timed function tests in Duchenne muscular dystrophy: imagingDMD cohort natural history. Muscle Nerve 58(5):631\u2013638","journal-title":"Muscle Nerve"},{"issue":"5","key":"9642_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","volume":"86","author":"D Gloss","year":"2016","unstructured":"Gloss D, Moxley RT, Ashwal S, Oskoui M (2016) Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 86(5):465\u2013472","journal-title":"Neurology."},{"issue":"1","key":"9642_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, DMD Care Considerations Working Group (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9(1):77\u201393","journal-title":"Lancet Neurol."},{"issue":"3\u20134","key":"9642_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000488244","volume":"50","author":"DC Salzberg","year":"2018","unstructured":"Salzberg DC, Mann JR, McDermott S (2018) Differences in race and ethnicity in muscular dystrophy mortality rates for males under 40 Years of Age, 2006\u20132015. Neuroepidemiology. 50(3\u20134):201\u2013206","journal-title":"Neuroepidemiology."},{"key":"9642_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","volume":"34","author":"S Guiraud","year":"2017","unstructured":"Guiraud S, Davies KE (2017) Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr Opin Pharmacol 34:36\u201348","journal-title":"Curr Opin Pharmacol"},{"key":"9642_CR18","unstructured":"Drug Development Pipeline [Internet]. Parent Project Muscular Dystrophy. [cited 2019 Jan 9]. \n                    https:\/\/www.parentprojectmd.org\/research\/current-research\/drug-development-pipeline\/"},{"key":"9642_CR19","unstructured":"Search of: Recruiting, Not yet recruiting Studies | Interventional Studies | Duchenne Muscular Dystrophy\u2014List Results\u2014ClinicalTrials.gov [Internet]. [cited 2019 Jan 9]. \n                    https:\/\/clinicaltrials.gov\/ct2\/results?recrs=ab&type=Intr&cond=Duchenne+Muscular+Dystrophy"},{"issue":"1","key":"9642_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mus.23807","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT, Han JJ, Escolar DM, Florence JM, Duong T, Arrieta A, Clemens PR, Hoffman EP, Cnaan A (2013) The cooperative international neuromuscular research group duchenne natural history study\u2014a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 48(1):32\u201354","journal-title":"Muscle Nerve"},{"issue":"2","key":"9642_CR21","first-page":"149","volume":"87","author":"V Ricotti","year":"2016","unstructured":"Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, Manzur AY, Muntoni F, UK NorthStar Clinical Network (2016) The NorthStar ambulatory assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry 87(2):149\u2013155","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"9642_CR22","doi-asserted-by":"publisher","first-page":"e108205","DOI":"10.1371\/journal.pone.0108205","volume":"9","author":"M Pane","year":"2014","unstructured":"Pane M, Mazzone ES, Sivo S, Sormani MP, Messina S, D\u2019Amico A, Carlesi A, Vita G, Fanelli L, Berardinelli A, Torrente Y, Lanzillotta V, Viggiano E, Ambrosio DP, Cavallaro F, Frosini S, Barp A, Bonfiglio S, Scalise R, De Sanctis R, Rolle E, Graziano A, Magri F, Palermo C, Rossi F, Donati MA, Sacchini M, Arnoldi MT, Baranello G, Mongini T, Pini A, Battini R, Pegoraro E, Previtali S, Bruno C, Politano L, Comi GP, Bertini E, Mercuri E (2014) Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS ONE 9(10):e108205","journal-title":"PLoS ONE"},{"key":"9642_CR23","unstructured":"A study of Tadalafil for Duchenne Muscular Dystrophy\u2014full text view\u2014ClinicalTrials.gov [Internet]. [cited 2019 Jan 9]. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01865084"},{"key":"9642_CR24","unstructured":"Open label study of GSK2402968 in subjects with Duchenne muscular dystrophy\u2014full text view\u2014ClinicalTrials.gov [Internet]. [cited 2019 Jan 9]. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01480245"},{"key":"9642_CR25","unstructured":"Phase 2b study of PTC124 in Duchenne\/Becker muscular dystrophy (DMD\/BMD)\u2014full text view\u2014ClinicalTrials.gov [Internet]. [cited 2019 Jan 9]. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00592553"},{"key":"9642_CR26","unstructured":"A phase 2 study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of PF-06252616 in Duchenne muscular dystrophy\u2014full text view\u2014ClinicalTrials.gov [Internet]. [cited 2019 Jan 9]. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02310763"},{"issue":"3","key":"9642_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.nmd.2016.11.013","volume":"27","author":"N Goemans","year":"2017","unstructured":"Goemans N, Tulinius M, Kroksmark A-K, Wilson R, van den Hauwe M, Campion G (2017) Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids. Neuromuscul Disord NMD. 27(3):203\u2013213","journal-title":"Neuromuscul Disord NMD."},{"issue":"4","key":"9642_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","volume":"87","author":"L Bello","year":"2016","unstructured":"Bello L, Morgenroth LP, Gordish-Dressman H, Hoffman EP, McDonald CM, Cirak S, CINRG investigators (2016) DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology. 87(4):401\u2013409","journal-title":"Neurology."},{"issue":"1","key":"9642_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JND-180337","volume":"6","author":"CR Senesac","year":"2019","unstructured":"Senesac CR, Lott DJ, Willcocks RJ, Duong T, Smith BK (2019) Lower extremity functional outcome measures in duchenne muscular dystrophy-a Delphi survey. J Neuromuscul Dis. 6(1):75\u201383","journal-title":"J Neuromuscul Dis."},{"key":"9642_CR30","unstructured":"joebenclark. Duchenne muscular dystrophy v1.0 [Internet]. CDISC. 2017 [cited 2019 Jan 9]. \n                    https:\/\/www.cdisc.org\/standards\/therapeutic-areas\/duchenne-muscular-dystrophy\/duchenne-muscular-dystrophy-v10"},{"issue":"6","key":"9642_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10928-014-9375-z","volume":"41","author":"DJ Conrado","year":"2014","unstructured":"Conrado DJ, Denney WS, Chen D, Ito K (2014) An updated Alzheimer\u2019s disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM. J Pharmacokinet Pharmacodyn 41(6):581\u2013598","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"9642_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35(4):401\u2013421","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"9642_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","volume":"11","author":"M Bergstrand","year":"2009","unstructured":"Bergstrand M, Karlsson MO (2009) Handling data below the limit of quantification in mixed effect models. AAPS J 11(2):371\u2013380","journal-title":"AAPS J"},{"issue":"9","key":"9642_CR34","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2012.12.008","volume":"61","author":"G Schram","year":"2013","unstructured":"Schram G, Fournier A, Leduc H, Dahdah N, Therien J, Vanasse M, Khairy P (2013) All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol 61(9):948\u2013954","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"9642_CR35","first-page":"121","volume":"31","author":"L Passamano","year":"2012","unstructured":"Passamano L, Taglia A, Palladino A, Viggiano E, D\u2019Ambrosio P, Scutifero M, Rosaria Cecio M, Torre V, Luca DE, Picillo E, Paciello O, Piluso G, Nigro G, Politano L (2012) Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol 31(2):121\u2013125","journal-title":"Acta Myol"},{"issue":"2","key":"9642_CR36","first-page":"117","volume":"31","author":"S Rall","year":"2012","unstructured":"Rall S, Grimm T (2012) Survival in Duchenne muscular dystrophy. Acta Myol 31(2):117\u2013120","journal-title":"Acta Myol"},{"issue":"6","key":"9642_CR37","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ejpn.2016.07.020","volume":"20","author":"HJA Van Ruiten","year":"2016","unstructured":"Van Ruiten HJA, Marini Bettolo C, Cheetham T, Eagle M, Lochmuller H, Straub V, Bushby K, Guglieri M (2016) Why are some patients with Duchenne muscular dystrophy dying young: an analysis of causes of death in North East England. Eur J Paediatr Neurol 20(6):904\u2013909","journal-title":"Eur J Paediatr Neurol"},{"key":"9642_CR38","first-page":"1137","volume":"14","author":"R Kohavi","year":"1995","unstructured":"Kohavi R (1995) A study of cross-validation and bootstrap for accuracy estimation and model selection. Ijcai 14:1137\u20131145","journal-title":"Ijcai"},{"key":"9642_CR39","unstructured":"Research C for DE and development & approval process (Drugs)\u2014drug development tools: fit-for-purpose Initiative [Internet]. [cited 2019 Jan 10]. \n\n                    https:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/ucm505485.htm"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-019-09642-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-019-09642-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-019-09642-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T23:10:05Z","timestamp":1590189005000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-019-09642-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["9642"],"URL":"https:\/\/doi.org\/10.1007\/s10928-019-09642-7","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,24]]},"assertion":[{"value":"21 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The D-RSC Consortium includes Biophytis, Catabasis Pharmaceuticals, Mallinckrodt, Pfizer, Santhera Pharmaceuticals, Sarepta Therapeutics and Wave Life Sciences. The ImagingDMD Network is funded through NIH Grant RO1AR056973. KRA has served as a paid consultant, providing methodological advice, to; Abbvie, Amaris, Allergan, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Creativ-Ceutical, GSK, ICON\/Oxford Outcomes, Ipsen, Janssen, Eli Lilly, Merck, NICE, Novartis, NovoNordisk, Pfizer, PRMA, Roche and Takeda, and has received research funding from Association of the British Pharmaceutical Industry (ABPI), European Federation of Pharmaceutical Industries & Associations (EFPIA), Pfizer and Sanofi. He is a Partner and Director of Visible Analytics Limited, a healthcare consultancy company. CMM has served as a consultant for clinical trials for PTC Therapeutics, and outside the submitted work as a consultant for Biomarin, Sarepta, Eli Lilly, Pfizer, Santhera Pharmaceuticals, Cardero Therapeutics, Inc., Catabasis, Capricor Therapeutics, Astellas and FibroGen; serves on external advisory boards related to Duchenne muscular dystrophy for PTC Therapeutics, Eli Lilly, Sarepta Therapeutics, Santhera Pharmaceuticals, and Capricor; and reports grants from US Dept. of Education\/NIDRR, NIDILRR, US NIH\/NIAMS, US Dept. of Defense, and Parent Project Muscular Dystrophy US, during the conduct of the study. Project HERCULES, which supported MH, KRA and MC, is funded by Duchenne UK, Pfizer, PTC Therapeutics, Roche, Summit Therapeutics PLC, Sarepta Therapeutics Inc, Wave Life Sciences USA Inc, Solid Biosciences, Santhera Pharmaceuticals and Catabasis Pharmaceuticals.\u201d MC has served as a paid consultant, providing methodological advice, to ICON\/Oxford Outcomes and Roche. DChapman, LH and CV are employees and shareholders of Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}